SRR8613734
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.750
- INTERFERON_GAMMA_RESPONSE+0.680
- ALLOGRAFT_REJECTION+0.610
- IL6_JAK_STAT3_SIGNALING+0.420
- G2M_CHECKPOINT+0.370
- COMPLEMENT+0.330
- E2F_TARGETS+0.330
- INFLAMMATORY_RESPONSE+0.300
- PANCREAS_BETA_CELLS+0.280
- IL2_STAT5_SIGNALING+0.210
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- ANGIOGENESIS-0.480
- CHOLESTEROL_HOMEOSTASIS-0.420
- ADIPOGENESIS-0.390
- ESTROGEN_RESPONSE_EARLY-0.350
- HYPOXIA-0.340
- MYOGENESIS-0.330
- ESTROGEN_RESPONSE_LATE-0.320
- FATTY_ACID_METABOLISM-0.320
- OXIDATIVE_PHOSPHORYLATION-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0RT-01A-21R-A084-07 | — | D | 0.917 |
| 2 | BSR_11_0107_E3_S77 | — | D | 0.914 |
| 3 | MBCProject_5971_T1_RNA | — | D | 0.895 |
| 4 | SRR8942983 | — | — | 0.869 |
| 5 | SRR8613787 | — | D | 0.869 |
| 6 | SRR8518222 | — | D | 0.866 |
| 7 | SRR5088834 | — | — | 0.865 |
| 8 | SRR25617828 | — | D | 0.863 |
| 9 | TCGA-AR-A1AW-01A-21R-A12P-07 | — | D | 0.859 |
| 10 | TCGA-43-A475-01A-11R-A24H-07 | — | cohortSQ2 | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.750 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.680 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.610 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.080 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |